Policy & Regulation
Sensei Biotherapeutics Names Former Head of the National Cancer Institute to its Board of Directors
18 April 2019 - - US-based biopharmaceutical company Sensei Biotherapeutics, Inc has appointed Samuel Broder, M.D. to its board of directors, the company said.

Broder has more than 30 years of medical oncology and research experience.

He is the former director of the National Cancer Institute, the largest and most important Agency for cancer research, where he was appointed by president Ronald Reagan in 1989.

While at the NCI, Broder oversaw the development of numerous anti-cancer therapeutic agents, helped launch a number of large-scale clinical trials related to the prevention, diagnosis, and treatment of cancer and inaugurated the highly successful SPORE Program.

Most recently, he served as senior vice president and Health Sector Head at Intrexon Corp.

Broder spent his entire career in translational medicine and his laboratory interests have included antiretroviral therapy, the relationship between immunodeficiency disorders and cancer, the human genome, and the proteomics of cancer cells. In the mid-1980s, in response to the AIDS pandemic, he focused his attention on HIV-1/AIDS.

His laboratory played a major role in developing the first 3 agents approved by FDA specifically to treat the AIDS virus, Retrovir, Videx, and HIVID.

After serving as the director of the NCI from 1989-1995, Dr. Broder served as senior vice president, Research and Development and chief scientific officer at IVAX Corp.

He then joined the Celera Corp., as the executive vice president for Medical Affairs and chief medical officer, and helped advance the human genome project, the elucidation of the 3bn letters of code that make up human DNA. He has received numerous scientific awards related to his research in cancer and AIDS.

He was elected to the Institute of Medicine of the National Academy of Sciences in 1993.

Sensei Biotherapeutics is a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies to transform the cancer treatment landscape.

The company is using its proprietary drug discovery platform, called SPIRIT, to discover and develop both vaccines and T-cell therapies, including SNS-301, its clinical stage cancer vaccine, and SNS-723, its cell therapy program in preclinical development for solid tumors and hematological cancers.

These programmes target ASPH, a novel embryonic antigen. Sensei's precision medicine approach in immuno-oncology includes the use of companion diagnostics to select patients who are most likely to respond to its tumor-specific antigen therapies. Sensei Biotherapeutics is located in Gaithersburg, MD.
Login
Username:

Password:


Related Headlines